Daily Stock Analysis, ABBV, AbbVie Inc, priceseries

AbbVie Inc. Daily Stock Analysis
Stock Information
Open
65.55
Close
65.44
High
65.62
Low
64.80
Previous Close
65.58
Daily Price Gain
-0.14
YTD High
67.50
YTD High Date
Apr 27, 2017
YTD Low
58.69
YTD Low Date
Jan 30, 2017
YTD Price Change
4.26
YTD Gain
6.97%
52 Week High
67.50
52 Week High Date
Apr 27, 2017
52 Week Low
53.97
52 Week Low Date
Oct 28, 2016
52 Week Price Change
8.34
52 Week Gain
14.61%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 8. 2015
54.14
May 1. 2015
59.91
17 Trading Days
10.66%
Link
LONG
Oct 29. 2015
51.06
Nov 11. 2015
57.74
9 Trading Days
13.09%
Link
LONG
Apr 1. 2016
54.76
Apr 28. 2016
57.67
19 Trading Days
5.32%
Link
Company Information
Stock Symbol
ABBV
Exchange
NYSE
Company URL
www.abbvie.com
Company Phone
(847) 932-7900
CEO
Richard A. Gonzalez
Headquarters
Illinois
Business Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL 60064
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001551152
About

AbbVie, Inc. is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products. The company's focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on January 1, 2013 and is headquartered in North Chicago, IL.

Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; and Infinity Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.